

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5789147

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the THE INCLUSION OF APPLICATION NO. 16/322,289 AS IT IS THE INCORRECT NUMBER AND SHOULD NOT HAVE BEEN INCLUDED IN THE ASSIGNMENT previously recorded on Reel 049989 Frame 0412. Assignor(s) hereby confirms the ASSIGNMENT.
RESUBMIT DOCUMENT ID:	505620754

CONVEYING PARTY DATA

Name	Execution Date
BAYER HEALTHCARE LLC	05/07/2019

RECEIVING PARTY DATA

Name:	COAGULANT THERAPEUTICS CORPORATION
Street Address:	RESEARCH BUILDING, SEOUL BIOHUB
Internal Address:	117-3 HOEGI-RO, DONGDAEMUN-GU
City:	SEOUL
State/Country:	KOREA, REPUBLIC OF
Postal Code:	02455

PROPERTY NUMBERS Total: 5

Property Type	Number
Patent Number:	10273466
Application Number:	14654581
Application Number:	15265703
Application Number:	16332289
Application Number:	62393930

CORRESPONDENCE DATA

Fax Number: (614)224-3246

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 317-236-2483

Email: ipdocketcolumbus@icemiller.com

Correspondent Name: CHRISTINE HANSEN, ICE MILLER LLP

Address Line 1: ONE AMERICAN SQUARE SUITE 2900

Address Line 4: INDIANAPOLIS, INDIANA 46282

ATTORNEY DOCKET NUMBER:	063851.00001
NAME OF SUBMITTER:	CHRISTINE M. HANSEN

PATENT

SIGNATURE:	/Christine M. Hansen/
DATE SIGNED:	10/25/2019
Total Attachments: 8 source=Cover Sheet filed 8-7-2019#page1.tif source=Cover Sheet filed 8-7-2019#page2.tif source=Assignment#page1.tif source=Assignment#page2.tif source=Assignment#page3.tif source=Assignment#page4.tif source=Assignment#page5.tif source=Assignment#page6.tif	

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BAYER HEALTHCARE LLC	05/07/2019
RECEIVING PARTY DATA	
Name:	COAGULANT THERAPEUTICS CORPORATION
Street Address:	RESEARCH BUILDING, SEOUL BIOHUB
Internal Address:	117-3 HOEGI-RO, DONGDAEMUN-GU
City:	SEOUL
State/Country:	KOREA, REPUBLIC OF
Postal Code:	02455
PROPERTY NUMBERS Total: 6	
Property Type	Number
Application Number:	14654581
Application Number:	15265703
Application Number:	62393930
PCT Number:	US2017050887
Application Number:	16322289
Patent Number:	10273466
CORRESPONDENCE DATA	
Fax Number:	(317)294-2953
Phone:	317-236-2483
Email:	ipdocket@icemiller.com, ann.braun@icemiller.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	CHRISTINE M. HANSEN, ICE MILLER LLP
Address Line 1:	ONE AMERICAN SQUARE SUITE 2900
Address Line 4:	INDIANAPOLIS, INDIANA 46282
ATTORNEY DOCKET NUMBER:	63851.0001

NAME OF SUBMITTER:	CHRISTINE M. HANSEN
Signature:	/Christine M. Hansen/
Date:	08/07/2019
Total Attachments: 6 source=Signed APA Scan May 22 2019-c#page1.tif source=Signed APA Scan May 22 2019-c#page2.tif source=Signed APA Scan May 22 2019-c#page3.tif source=Signed APA Scan May 22 2019-c#page4.tif source=Exhibit A of APA-c#page1.tif source=Exhibit A of APA-c#page2.tif	
RECEIPT INFORMATION	
EPAS ID:	PAT5657302
Receipt Date:	08/07/2019

PATENT ASSIGNMENT AGREEMENT

This PATENT ASSIGNMENT AGREEMENT ("Agreement"), is entered into as of May 7, 2019 (the "Effective Date"), by and between Bayer HealthCare LLC, a Delaware limited liability company ("Seller"), and Coagulant Therapeutics Corporation, a corporation duly incorporated and registered under the laws of the Republic of Korea ("Buyer"). Reference is made to the Asset Purchase Agreement, dated April 10, 2019 (the "Asset Purchase Agreement"), by and between Seller and Buyer. Capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Asset Purchase Agreement.

RECITALS

WHEREAS, pursuant to the Asset Purchase Agreement, Seller has agreed to sell, convey, transfer, assign and deliver to Buyer all of the Assets, and Buyer has agreed to purchase the Assets from Seller;

WHEREAS, Seller is the sole owner of certain patents, patent applications and invention disclosures as set forth in Exhibit A of the Asset Purchase Agreement and attached hereto as Exhibit A (the "Assigned Patents and Applications");

WHEREAS, pursuant to the Asset Purchase Agreement, Seller has agreed that Seller shall, among other things, irrevocably transfer and assign to Buyer all of Seller's ownership in and to the Assigned Patent and Applications as set forth herein; and

WHEREAS, the parties hereto desire to effectuate the assignment of Seller's right, title and interest in and to the Assigned Patents and Applications.

NOW, THEREFORE, in consideration of the covenants, representations and warranties contained in the Asset Purchase Agreement, and the Recitals set forth above, and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:

AGREEMENT

1. Assignment. Effective as of Effective Date, Seller hereby irrevocably sells, assigns, transfers, conveys and sets over to Buyer and its successors and assigns all of Seller's right, title and interest in and to the Assigned Patents and Applications to the full extent of its ownership or interest therein; all rights to causes of action and remedies related thereto (including, without limitation, the right to sue for present or future infringement, misappropriation or violation of rights related to the foregoing); and any and all other rights and interests arising out of, in connection with or in relation to the Assigned Patents and Applications.
2. Further Assurances. Promptly following the Effective Date, Seller agrees to execute and deliver all additional instruments and documents reasonably requested by Buyer for the purposes of effectuating a full assignment, transfer, and conveyance of Seller's interest in and to the Assigned Patents and Applications to Buyer.

3. Costs. Buyer shall be solely responsible for and bear all costs, fees and expenses, including Buyer's attorneys' fees, with respect to the assignment, registration, maintenance, protection and enforcement of the Assigned Patents and Applications from and after the Effective Date, including the patent office fees in any jurisdiction associated with the recordation or filing of any assignment of the Assigned Patents and Applications to Buyer.
4. Subject to the Asset Purchase Agreement. This Agreement is subject in all respects to the terms and conditions of the Asset Purchase Agreement, and all of the representations, warranties, covenants and agreements of the Seller and Buyer contained therein, all of which shall survive the execution and delivery of this Agreement in accordance with the terms of the Asset Purchase Agreement. The Assigned Patents and Applications are being delivered for good and valuable consideration, pursuant to the terms and conditions contained in the Asset Purchase Agreement. Nothing contained herein shall supersede, amend, alter or modify (nor shall it be deemed or construed to supersede, amend, alter or modify) any of the terms or conditions of the Asset Purchase Agreement in any manner whatsoever. In the event of any conflict between the provisions of this Agreement and the provisions of the Asset Purchase Agreement, the provisions of the Asset Purchase Agreement shall control and prevail.
5. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original but all of which together shall constitute one and the same instrument.
6. Modification. This Agreement may be amended or modified only by a written instrument executed by the parties hereto.
7. Waiver. No omission or delay by any party in exercising any right, power or privilege hereunder shall impair the exercise of any such right, power or privilege or be construed to be a waiver hereof or of any default or to be an acquiescence therein, and any single or partial exercise of any such right, power or privilege shall not preclude other or further exercises thereof or the exercise of any other right, power or privilege. No waiver shall be valid unless in writing and signed by the party to be charged, and then only to the extent therein specified.
8. Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
9. Binding Effect; Assignment. The rights and obligations of this Agreement shall bind and inure to the benefit of the parties and their respective successors and assigns. Nothing expressed or implied herein shall be construed to give any other person any legal or equitable rights hereunder.
10. Governing Law. This Agreement shall be governed by and construed and enforced in accordance with laws of the State of California without reference to the conflicts of law principles thereof.

11. Entire Agreement. This Agreement, together with the Exhibit hereto which is incorporated herein by reference, constitutes the entire agreement between and among the parties with regard to the subject matter hereof. This Agreement supersedes all previous agreements and understandings, whether written or oral, between or among the parties with respect to the subject matter hereof.

[Signature Page Follows]

24131571.2

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized as of the date first above written.

SELLER:

BAYER HEALTHCARE LLC
a Delaware limited liability company

By: *R. [Signature]*
Name: GUERU RAMANUJAN
Title: VP FINANCE



BUYER:

COAGULANT THERAPEUTICS CORPORATION,
a corporation of the Republic of Korea

By: *Terry Hermsdorf*
Name: Terry Hermsdorf
Title: CEO & Founder

Exhibit A

Bayer Patents

1. Patents/Applications

a. Active Maxygen-Acquired Factor VII Patents

Bayer Reference No.	Application Serial No.	Publication No.	Patent No.
MXYN 0274 US05	11/424030	US2006/0240526	US 7,807,638
MXYN 0274 US04	11/424035	US2006/0241041	US 8,987,202
MXYN 0272 US02	10/549506	US2007/0054366	US 7,771,996
MXYN 0259 US06	12/707453	US2010/0260741	US 9,353,365
MXYN 0259 US01	10/512754	US2006/0111282	US 7,700,733
MXYN 0212 US13	11/928108	US2009/0023635	US 7,754,682
MXYN 0212 US12	11/426401	US2006/0232690	US 7,414,022
MXYN 0212 US10	11/423665	US2006/0240525	US 7,427,592
MXYN 0212 US09	11/423662	US2006/0240524	US 7,442,524
MXYN 0212 US08	11/423622	US2006/0228782	US 8,084,591
MXYN 0212 US06	11/379189	US2006/0232127	US 7,598,056
MXYN 0212 US05	11/279541	US2007/0243588	US 7,511,024
MXYN 0212 US04	11/396314	US2006/0258585	US 7,517,974
MXYN 0212 US02	09/782587	US2003/0096338	US 6,806,063
MXYN 0281 EP	06700982.9	WO2006/074664	EP1841863
MXYN 0285 EP	06800183.3	WO2007/013993	EP1907540

b. Bayer Factor VII Applications

i. BHC 115011 - Short-Acting Factor VII Polypeptides

1. WO 2014/105784 - Published 3 July 2014
2. Filed in the following countries:

Country	Bayer Ref	Application Serial No.	Filing Date
AR	BHC115011 AR	20130105071	27 Dec 2013
AU	BHC115011 PCT-AU	2013370522	23 Dec 2013
BR	BHC115011 PCT-BR	BR112015015182-5	23 Dec 2013
CA	BHC115011 PCT-CA	2,896,057	23 Dec 2013
CN	BHC115011 PCT-CN	201380073743.5	23 Dec 2013
CN	BHC115011 PCT-CN D	201610960730.5	4 Nov 2016
EP	BHC115011 PCT-EP	13867801.6	23 Dec 2013
EP	BHC115011 PCT-EP-D	16196780.7	2 Nov 2016
HK	BHC115011 HK	16104910.1	23 Dec 2013
HK	BHC115011 HK-D	18102170.8	12 Feb 2018
IL	BHC115011 PCT-IL	239345	23 Dec 2013
IN	BHC115011 PCT-IN	3611/CHENP/2015	23 Dec 2013
JP	BHC115011 PCT-JP	2015-549857	23 Dec 2013
JP	BHC115011 PCT-JP-D	2016-211992	23 Dec 2013
KR	BHC115011 PCT-KR	10-2015-7019457	23 Dec 2013
MX	BHC115011 PCT-MX	MX/a/2015/007712	23 Dec 2013
MX	BHC115011 PCT-MX-D	MX/a/2016/015101	17 Nov 2016
NZ	BHC115011 PCT-NZ	708873	23 Dec 2013

Country	Bayer Ref	Application Serial No.	Filing Date
NZ	BHC115011 PCT-NZ D	749488	23 Dec 2013
PE	BHC115011 PCT-PE	1020-2015	23 Dec 2013
SA	BHC115011 PCT-SA	513360668	23 Dec 2013
SA	BHC115011 PCT-SA-D	517380867	23 June 2015
SG	BHC115011 PCT-SG	11201504986Q	23 Dec 2013
SG	BHC115011 PCT-SG D	10201710593U	20 Dec 2017
TW	BHC115011 TW	102147863	23 Dec 2013
US	BHC115011 PCT-US	14/341,359	25 Jul 2014
US	BHC115011 PCT-US01	14/654,581	22 June 2015
US	BHC115011 PCT-US02	15/265,703	14 Sept 2016
ZA	BHC115011 PCT-ZA	2015/05315	23 Dec 2013
ZA	BHC115011 PCT ZA D	2016/07236	20 Oct 2016

ii. BHC 145015 -- Factor VIIa Glycoforms

1. US Provisional Application No. 62/393,930 - Filed 13 September 2016
2. PCT Application No. - PCT/US2017/050887
3. Nationalization due 13 March 2019

2. Invention Disclosures

- a. BHC 145011 IDF -- An invention disclosure form was submitted disclosing sialylation deficient CHO-K1 cell lines. No patent filing was pursued.
- b. BHC 145012 IDF -- An invention disclosure form was submitted disclosing detailed purification methods for desialylated FVII. No patent filing was pursued.
- c. BHC 145013 IDF - An invention disclosure form was submitted disclosing a method to select cells that desialylate using a recombinant sialidase gene and are optimized for viability and productivity. No patent filing was pursued.